In July 2017, the Chinese CRO giant, WuXi AppTec, has disclosed its attempt for an IPO. In a report, it is slated to raise around $800 million, and if it is successful, WuXi AppTec is set to break the largest fundraising record of the Chinese biomedical industry in the past six years. Wuxi AppTec, the …

Read Article Read More

On September 7th, Eli Lilly, the US Pharma giant, closed its Zhangjiang research center in China, just a month after GlaxoSmithKline (GSK)’s ended its neuroscience unit in Shanghai. Andrew Hodge, the president and general manager of Lilly China, announced the news to the Chinese employees. He stressed that the move is slated to optimize the …

Read Article Read More